FIGURE 7.

AMI regulates expression of neurotrophic proteins and improves motor function of WT mice. A, AMI-mediated alteration in expression levels of striatal proteins associated with BDNF-induced neurotrophic activity and synaptic structure measured using Western blot. B, ProBDNF. C, mature BDNF. D, TrkB receptor activity, i.e. ratio of phosphorylated (p)-TrkB/TrkB; E, CREB activity, i.e. ratio of p-CREB/CREB in striatum; F, ERK activity, i.e. ratio of p-ERK/ERK; G, AKT activity, i.e. ratio of p-AKT/AKT; H, GSK3β activity, i.e. ratio of p-GSK3β/GSK3β; I, ratio of p-DARPP32/DARPP32; J, DCX; K, synaptophysin (SYP); L, PSD95. Data from three animals of each group are expressed as means ± S.E. *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. (Control treatment, Con; AMI treatment, AMI). M, rotarod performance change curves throughout 6-week AMI treatment (vehicle-treated, black line; AMI-treated, gray line). N, mean latency time to reach the goal box in the walking beam task. O, mean number of foot slips of WT mice (AMI-treated and vehicle-treated) in the walking beam task. Data from 12 animals of each group are expressed as means ± S.E. *, p ≤ 0.05. (Control treatment, Con; AMI treatment, AMI).